Long term results of surgery and chemotherapy in small cell lung cancer
| Autor: | F, Rea, D, Callegaro, A, Favaretto, M, Loy, A, Paccagnella, U, Fantoni, G, Festi, F, Sartori |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male Lung Neoplasms Antineoplastic Agents Postoperative Complications Antineoplastic Combined Chemotherapy Protocols Humans Longitudinal Studies Prospective Studies Carcinoma Small Cell Pneumonectomy Antineoplastic Agents Alkylating Cyclophosphamide Aged Epirubicin Etoposide Neoplasm Staging Antibiotics Antineoplastic Middle Aged Antineoplastic Agents Phytogenic Survival Rate Chemotherapy Adjuvant Doxorubicin Vincristine Female Radiotherapy Adjuvant Cisplatin Cranial Irradiation Neoplasm Recurrence Local Follow-Up Studies |
| Zdroj: | European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 14(4) |
| ISSN: | 1010-7940 |
| Popis: | The aim of the study is to analyse long-term results of patients with small cell lung cancer (SCLC) treated at the same institution according to a prospective study including surgery, chemotherapy, and radiotherapy.From 1981 to 1995, 104 patients with a proven histology of SCLC underwent surgery, chemotherapy, and radiotherapy. Fifty-one patients with operable stage I or II lesion received surgical resection followed by adjuvant chemotherapy and radiotherapy. Fifty-three patients with proved SCLC and clinical stage III received induction chemotherapy followed by surgery and radiotherapy. All patients received from four to six courses of chemotherapy and 36 had prophylactic cranial irradiation (PCI). All patients had follow-up for at least 1 year, and survival time was calculated from the date of the diagnosis until death or most recent follow-up.Ninety-six patients were male and eight female. We performed 29 pneumonectomies, eight bilobectomies, 66 lobectomies and one no resection. Regarding the clinical stage, 35 patients (33.6%) had stage I, 16 patients (15.4%) had stage II and 53 (51%) had stage III. Post-operative pathologic staging revealed stage I in 37 patients (35.6%), stage II in nine patients (8.6%), stage III in 45 patients (43.3%), and in 13 patients (12.5%) there was no more tumor. The 30-day mortality was 2% (two patients). Fourteen patients (13.4%) had post-operative complications. Fifty-one patients (49%) had a relapse. The median follow-up was 55 months. Twenty-six patients remain alive and 78 patients have died. The overall 5-year survival rate was 32%, with an estimate median survival time of 28 months; according to the pathologic stage, the survival data were 52.2%, 30% and 15.3% for stage I, II and III, respectively (P0.001). The 5-year survival was 41% in patients without SCLC after chemotherapy.As with non-small cell lung cancer, survival following surgery and chemotherapy clearly correlates with the stage. At present, it is not clear whether surgery is truly effective for patients with SCLC. In our experience, the complete elimination of small cell lung cancer is associated with an improvement in survival (41% at 5 years). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|